Safety and Pharmacokinetics of Clindamycin in Pediatric Subjects With BMI ≥ 85th Percentile
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to better understand how clindamycin works in children who fall
in the 85th percentile or higher for body mass index (BMI - a ratio of weight to height). The
results of the study will help better understand if children in higher BMI ranges process the
medication differently and whether dosing should be adjusted in these children.
Phase:
Phase 1
Details
Lead Sponsor:
Phillip Brian Smith
Collaborators:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) The Emmes Company, LLC The EMMES Corporation